NCT03759184 2022-03-22
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
National Institutes of Health Clinical Center (CC)
Pfizer
Gilead Sciences
Bristol-Myers Squibb
University of California, San Diego